Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT01513759

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01513759
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01513759. Allocation not applicable; no masking; primary purpose treatment. Start 2012-06-07 (actual); primary completion 2013-02-17 (actual). Results posted on 2019-07-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
Acronym
SEATTLE II
Condition
Acute Pulmonary Embolism
Condition
Sub-massive Pulmonary Embolism
Condition
Massive Pulmonary Embolism
Condition
Pulmonary Thromboembolism
Intervention (Drug)
recombinant tissue plasminogen activator
Intervention (Device)
EKOS EkoSonic Endovascular System
Lead sponsor
Boston Scientific Corporation (class: industry)
Collaborator
EKOS Corporation (class: industry)

Record details

Record id
cardio:ct-nct01513759
Content hash
ed7babc8adafb14e56733238db3d581961ad44f3d64741b0632463522955becf